DP VII ASSOCIATES LP

Average Profitability
8.67%
Insider Buys Quantity
1
Insider Buys Sum
$134,148.00
Insider Sells Quantity
13
Insider Sells Sum
$89,023.10

Insider Activity of DP VII ASSOCIATES LP

The largest purchase of all time was on 2013-07-01 and amounted to 9582 shares of Esperion Therapeutics, Inc. for $134,148.

The largest sale of all time was on 2016-05-26 and amounted to 11760 shares of Evoke Pharma, Inc. for $55,272.

Biography of DP VII ASSOCIATES LP

No biography is available at this moment.

2016-05-26SaleEvoke Pharma, Inc.
EVOK
10 percent owner
11,760
0.1429%
$4.70$55,272-52.42%
2016-04-27SaleEvoke Pharma, Inc.
EVOK
10 percent owner
122
0.0018%
$5.02$612-46.99%
2016-04-25SaleEvoke Pharma, Inc.
EVOK
10 percent owner
42
0.0006%
$5.20$218-51.43%
2016-04-20SaleEvoke Pharma, Inc.
EVOK
10 percent owner
152
0.0022%
$5.29$804-50.19%
2016-04-19SaleEvoke Pharma, Inc.
EVOK
10 percent owner
1,264
0.0182%
$5.36$6,775-50%
2016-04-11SaleEvoke Pharma, Inc.
EVOK
10 percent owner
150
0.0021%
$5.22$783-50.1%
2016-04-08SaleEvoke Pharma, Inc.
EVOK
10 percent owner
502
0.0072%
$5.35$2,686-50.19%
2016-04-07SaleEvoke Pharma, Inc.
EVOK
10 percent owner
950
0.013%
$5.26$4,997-51.31%
2016-04-06SaleEvoke Pharma, Inc.
EVOK
10 percent owner
296
0.0041%
$5.22$1,545-49.9%
2015-08-18SaleEvoke Pharma, Inc.
EVOK
director
404
0.0085%
$7.02$2,836-28.63%
2015-04-16SaleEvoke Pharma, Inc.
EVOK
10 percent owner
1,108
0.0189%
$7.07$7,834-41.52%
2015-04-15SaleEvoke Pharma, Inc.
EVOK
10 percent owner
270
0.0044%
$7.58$2,047-47.58%
2015-04-14SaleEvoke Pharma, Inc.
EVOK
10 percent owner
336
0.0054%
$7.78$2,614-50.32%
2013-07-01PurchaseEsperion Therapeutics, Inc.
ESPR
10 percent owner
9,582
0.0624%
$14.00$134,148+8.67%
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.